Atlas Trials

Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors

Clinical trial NCT02456883 · COMPLETED

Trial details

NCT number
NCT02456883
Sponsor
Astellas Pharma Global Development, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Advanced Solid TumorsPharmacokinetics of 14C-labeled Gilteritinib
Start date
2016-03-04
Primary completion
2017-05-20
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.